---
title: "DEA Special Registration for Telemedicine: 2026 Status"
description: "DEA's special registration would let providers prescribe controlled drugs by telemedicine. Its status on Oct 26, 2026, and how Cuvo Health tracks the rule."
canonical: "https://cuvo.co/glossary/dea-special-registration-telemedicine"
last-updated: "Oct 26, 2026"
---
**Definition:** DEA special registration for telemedicine is a registration the Controlled Substances Act lets the DEA issue so a practitioner can prescribe controlled substances by telemedicine without a prior in-person evaluation; as of October 26, 2026, its final rule had not been published.

# What is DEA special registration for telemedicine?

The temporary DEA rule that lets providers prescribe testosterone and other controlled substances by telemedicine expires at the end of 2026, and the special registration is the permanent pathway Congress wrote into the statute for that kind of prescribing. Its final rule has been under review at the Office of Management and Budget since August 25, 2026. Cuvo Health tracks it for every brand on its platform and applies the rule in force to prescribing.

Published Oct 26, 2026. Facts reviewed Oct 26, 2026.

DEA special registration for telemedicine is a registration the Controlled Substances Act lets the DEA issue so a practitioner can prescribe controlled substances by telemedicine without first evaluating the patient in person. The Ryan Haight Act created it in 2008 (21 U.S.C. 831(h)), and the SUPPORT Act of 2018 gave DEA until October 24, 2019 to finalize the rules. DEA proposed them on January 17, 2025 (90 FR 6541). As of October 26, 2026, the final rule had been under review at the Office of Information and Regulatory Affairs since August 25, 2026 and had not been published. On Cuvo Health, DEA and telehealth rule tracking is included on every plan, so prescribing rules change on the platform when the final rule takes effect.

**At a glance**
- What it is: A DEA registration to prescribe controlled substances by telemedicine without a prior in-person exam
- Statute: 21 U.S.C. 831(h); final rules were due October 24, 2019
- Proposal: 90 FR 6541, January 17, 2025; comments closed March 18, 2025
- Status, Oct 26, 2026: Final rule at OIRA since August 25, 2026; not yet published
- On Cuvo: DEA and telehealth rule tracking on every plan

**What the January 2025 proposal would create (the final rule may differ)**

| Registration | Who would hold it | What it would allow |
| --- | --- | --- |
| **Telemedicine Prescribing Registration** | Qualified clinician practitioners | Prescribing Schedule III to V by telemedicine |
| **Advanced Telemedicine Prescribing Registration** | Specialized clinicians, such as psychiatrists and hospice physicians | Prescribing Schedule II to V by telemedicine |
| **Telemedicine Platform Registration** | Covered online telemedicine platforms | Dispensing Schedule II to V as platform practitioners |
| **State Telemedicine Registration** | Each special registrant, for every state where patients are treated | A DEA-issued state credential: $50 per state for clinicians, $888 for platforms |

## 01. Why does special registration matter for a telehealth brand?

It is the permanent pathway the statute provides for prescribing controlled substances to patients a practitioner has never seen in person. The temporary flexibilities that do that today expire at the end of December 31, 2026 (21 CFR 1307.41(a)). Under the January 2025 proposal, testosterone, a Schedule III drug, would fall under the Telemedicine Prescribing Registration, and some direct-to-consumer platforms would need a registration of their own: the proposal defines a covered online telemedicine platform as an entity that connects patients with clinicians by audio-video for diagnosis and treatment that may result in controlled substance prescriptions, excluding hospitals, clinics, local in-person practices and insurers, and meeting further criteria.

## 02. What would the proposed rule require of prescribers?

Special registration prescriptions would have to be sent by EPCS, after the registrant verifies the patient's identity and checks prescription drug monitoring programs: the patient's state, the prescriber's state and any reciprocity state at first, and every state and territory PDMP after three years. Each special registration would cost $888 on a three-year cycle, and the Advanced registration would cap Schedule II telemedicine prescriptions below 50 percent of the registrant's monthly Schedule II prescriptions. The final rule may change any of these terms.

## 03. What is the status of the special registration rule?

As of October 26, 2026: DEA received more than 6,475 comments on the proposal, according to its fourth temporary rule (90 FR 61301). The final rule was received for Executive Order 12866 review on August 25, 2026 and was still listed as under review in OIRA's report run on October 25, 2026. The Unified Agenda lists the final action for November 2026, and no final rule had appeared in the Federal Register. Cuvo's DEA telemedicine post tracks what applies on January 1, 2027.

## 04. How is it different from a standard DEA registration?

A standard registration authorizes a practitioner to handle controlled substances in a state where the practitioner is authorized under state law (21 U.S.C. 823(g)(1)). The special registration is one of the statutory exceptions to the in-person requirement (21 U.S.C. 802(54)(E)), and the statute still requires the practitioner to be registered in the state where the patient will be located (21 U.S.C. 831(h)(1)(B)), which the proposal meets with its DEA-issued State Telemedicine Registration. On Cuvo, every prescriber's DEA registration is verified during credentialing, and EPCS is included on Grow, Enterprise and Cuvo Prescribe.

## Frequently asked questions

**Q: What is the DEA special registration for telemedicine?**

A: It is a registration under 21 U.S.C. 831(h) that would let a practitioner prescribe controlled substances by telemedicine without a prior in-person evaluation, proposed by the DEA on January 17, 2025. On Cuvo, DEA and telehealth rule tracking is included on every plan, so the platform follows the rule in force.

**Q: Has the DEA special registration rule been finalized?**

A: Not as of October 26, 2026: the final rule had been under OIRA review since August 25, 2026, the Unified Agenda listed final action for November 2026, and nothing had been published in the Federal Register. Cuvo Health tracks the rule and applies it to prescribing on the platform when it takes effect.

**Q: Would a telehealth platform need a DEA special registration?**

A: Under the January 2025 proposal, a covered online telemedicine platform would need a Telemedicine Platform Registration and a State Telemedicine Registration for each state where patients are treated; the final rule may differ. On Cuvo, regulatory monitoring tracks the final text for every brand on the platform.

**Q: Special registration vs DEA registration: what is the difference?**

A: A standard DEA registration authorizes a practitioner in a state; the special registration is a separate pathway for prescribing by telemedicine without an in-person evaluation, and it still requires registration in the patient's state. On Cuvo, every prescriber's DEA registration is verified during credentialing.

**Q: Does a telehealth brand need a special registration to prescribe testosterone?**

A: Not today: testosterone prescribing by telemedicine runs under the DEA temporary flexibilities through December 31, 2026, and the proposal would place it under the Telemedicine Prescribing Registration once a final rule is in force. Cuvo Health runs testosterone programs with DEA-verified prescribers and EPCS on Grow and above, and tracks the rule for every brand.

**Related pages**

- [DEA telemedicine flexibilities in 2026](/blog/dea-telemedicine-flexibilities-2026): The Ryan Haight Act, the temporary rule and what comes next
- [DEA registration](/glossary/dea-registration): The standard registration every prescriber holds
- [Prescription drug monitoring program](/glossary/prescription-drug-monitoring-program): The PDMP checks the proposal would require
- [EPCS](/glossary/epcs): The prescribing rail the proposal would mandate
- [Cuvo compliance](/compliance): DEA rule tracking and 50-state monitoring
- [Telehealth glossary](/glossary): Every term a telehealth founder meets

Canonical page: https://cuvo.co/glossary/dea-special-registration-telemedicine